CPH · NOVO-B.CO
Novo Nordisk A/S
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
Loading market information…
CPH · DEMANT.CO · DKK
Stock price, earnings
Quote as of Oct 29, 2026, 03:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · DKK. Historical prices are not a forecast.
Demant A/S’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Demant A/S’s next earnings report is currently expected on Feb 9, 2027, with estimated earnings per share of DKK 7.94. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Demant A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Demant A/S operates as a prominent international entity within the hearing health and audio technology sectors, extending its reach across Europe, North America, the Pacific region, and Asia. The company's activities are structured into two core divisions: Hearing Healthcare and Communications. The Hearing Healthcare segment focuses on the development, sale, and support of hearing aids, in addition to offering a range of diagnostic tools and associated services. Conversely, the Communications segment delivers headsets for professional contact centers, general office environments, and the gaming industry, all distributed under the EPOS brand. Established in 1904, Demant A/S, which was formerly known as William Demant Holding A/S until its name change in March 2019, maintains its corporate headquarters in Smørum, Denmark.
Latest available per-share figures in DKK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | May 6, 2024 | DKK 5.81-2.68% vs estimate | DKK 11.29B-0.38% vs estimate |
|---|
| Q4 2023 | Feb 6, 2024 | DKK 5.63+24.28% vs estimate | DKK 11.16B+0.38% vs estimate |
|---|
| Q4 2022 | Feb 7, 2023 | DKK 4.61-6.87% vs estimate | DKK 10.11B+2.27% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
DKK 3,788.00-DKK 80.00 (-2.07%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
DKK 477.00-DKK 1.50 (-0.31%)
Coloplast A/S’s quoted price sits in the lower half of its reported 52-week range, 24.45% below the high.
DKK 246.60+DKK 3.00 (+1.23%)
ALK-Abelló A/S’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
DKK 54.45+DKK 1.65 (+3.13%)
H. Lundbeck A/S’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
DKK 110.20-DKK 2.55 (-2.26%)
GN Store Nord A/S’s quoted price sits in the upper half of its reported 52-week range, 10.95% below the high.
DKK 101.00+DKK 1.80 (+1.81%)
RTX A/S’s quoted price sits in the lower half of its reported 52-week range, 15.83% below the high.
